Cytokinetics, Incorporated (CYTK)
Fuera de horario:
Cytokinetics, Incorporated
350 Oyster Point Boulevard
South San Francisco, CA 94080
United States
650 624 3000
https://www.cytokinetics.com
Sector(es): Healthcare
Industria: Biotechnology
Empleados a tiempo completo: 423
Ejecutivos clave
| Nombre | Título | Pagar | Ejecutado | Año de nacimiento |
|---|---|---|---|---|
| Mr. Robert I. Blum | CEO, President, Principal Financial Officer & Director | 1.33M | 9.61M | 1964 |
| Mr. Robert C. Wong | VP & Chief Accounting Officer | 495.72k | N/D | 1968 |
| Dr. Fady Ibraham Malik FACC, M.D., Ph.D. | Executive Vice President of Research & Development | 839.66k | 586.17k | 1964 |
| Mr. Andrew M. Callos | Executive VP & Chief Commercial Officer | 752.84k | N/D | 1969 |
| Dr. James A. Spudich Ph.D. | Co-Founder & Member of Scientific Advisory Board | 21.94k | N/D | 1942 |
| Mr. Jeff Lotz | Vice President of Sales & Operations | N/D | N/D | N/D |
| Mr. Matt Yang | Vice President of Corporate Finance and Financial Planning & Analysis | N/D | N/D | N/D |
| Mr. Steven M. Cook | Senior Vice President of Global Supply Chain Operations & Technical Operations | N/D | N/D | 1959 |
| Ms. Kari K. Loeser J.D. | VP & Chief Compliance Officer | N/D | N/D | N/D |
| Mr. John O. Faurescu Esq. | VP, Associate General Counsel & Corporate Secretary | N/D | N/D | N/D |
Descripción
Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator that is in Phase III clinical trial in patients with heart failure. The company also develops CK-136, a novel cardiac troponin activator that is in Phase I clinical trial; CK-586, a small molecule cardiac myosin inhibitor, that is in Phase I clinical trial; and aficamten, a novel cardiac myosin inhibitor, which is in Phase III clinical trial for the treatment of patients with symptomatic obstructive hypertrophic cardiomyopathy. Cytokinetics, Incorporated has a strategic alliance with Ji Xing Pharmaceuticals Limited. The company was incorporated in 1997 and is headquartered in South San Francisco, California.
Gestión corporativa
La calificación ISS Governance QuickScore de Cytokinetics, Incorporated a partir del 1 de abril de 2024 es 5. Las puntuaciones principales son Auditoría: 6; Junta: 3; Derechos del accionista: 7; Compensación: 6.
